(Q37927122)

25 August 2017

1 reference

title

Parallel use of by-passing agents in haemophilia with inhibitors: a critical review (English)

1 reference

25 August 2017

Parallel use of by‐passing agents in haemophilia with inhibitors: a critical review (English)

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2011.08854.X

11 December 2024

0 references

Jørgen Ingerslev

1 reference

25 August 2017

Benny Sørensen

series ordinal

1 reference

25 August 2017

language of work or name

English

0 references

publication date

7 September 2011

1 reference

full work available at URL

25 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2141.2011.08854.x

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2011.08854.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.2011.08854.x

11 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2011.08854.X

British Journal of Haematology

11 December 2024

published in

1 reference

25 August 2017

volume

155

1 reference

25 August 2017

1 reference

25 August 2017

page(s)

256-262

1 reference

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Surgery in patients with haemophilia and high responding inhibitors: Izmir experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

The use of combination FEIBA and rFVIIa bypassing therapy, with TEG profiling, in uncontrollable bleeding associated with acquired haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

International recommendations on the diagnosis and treatment of patients with acquired hemophilia A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

How we treat a hemophilia A patient with a factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Thromboelastography and recombinant factor VIIa-hemophilia and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

21 January 2018

FEIBA: mode of action

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08854.X

Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2011.08854.X

Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor--clinical outcome and laboratory observations

11 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2011.08854.X

11 December 2024

Identifiers

1 reference

25 August 2017

1 reference